Recursion Pharma Amends Equity Filing
Ticker: RXRX · Form: 8-K/A · Filed: Nov 26, 2024 · CIK: 1601830
| Field | Detail |
|---|---|
| Company | Recursion Pharmaceuticals, Inc. (RXRX) |
| Form Type | 8-K/A |
| Filed Date | Nov 26, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.00001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, equity-securities, filing-correction
Related Tickers: RXRX
TL;DR
Recursion Pharma filed an amendment to an equity sale filing from August 8, 2024.
AI Summary
Recursion Pharmaceuticals, Inc. filed an 8-K/A on November 26, 2024, to amend a previous filing regarding unregistered sales of equity securities. The original event date reported was August 8, 2024. The filing does not provide specific details on the equity sold or the parties involved.
Why It Matters
This amendment to a previous filing indicates a correction or addition to information about unregistered equity sales, which could be relevant for investors tracking the company's capital structure and potential dilution.
Risk Assessment
Risk Level: low — This is an amendment to a previous filing and does not introduce new material events or financial information.
Key Players & Entities
- Recursion Pharmaceuticals, Inc. (company) — Registrant
- August 8, 2024 (date) — Earliest event reported date
- November 26, 2024 (date) — Filing date
FAQ
What specific information is being amended in the August 8, 2024 filing?
The filing is an 8-K/A, indicating an amendment to a previous report concerning unregistered sales of equity securities. However, the specific details of the amendment are not provided in the provided text.
What was the original event date for the filing being amended?
The original event date reported for the filing being amended was August 8, 2024.
What is the filing type and date?
The filing type is Form 8-K/A, and it was filed as of November 26, 2024.
What is the primary business of Recursion Pharmaceuticals, Inc.?
Recursion Pharmaceuticals, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Where is Recursion Pharmaceuticals, Inc. headquartered?
Recursion Pharmaceuticals, Inc. is headquartered at 41 S Rio Grande Street, Salt Lake City, UT 84101.
Filing Stats: 734 words · 3 min read · ~2 pages · Grade level 12.2 · Accepted 2024-11-26 16:48:25
Key Financial Figures
- $0.00001 — stered Class A Common Stock, par value $0.00001 per share RXRX Nasdaq Global Select Mar
Filing Documents
- rxrx-20240808.htm (8-K/A) — 21KB
- 0001601830-24-000224.txt ( ) — 152KB
- rxrx-20240808.xsd (EX-101.SCH) — 2KB
- rxrx-20240808_def.xml (EX-101.DEF) — 3KB
- rxrx-20240808_lab.xml (EX-101.LAB) — 23KB
- rxrx-20240808_pre.xml (EX-101.PRE) — 14KB
- rxrx-20240808_htm.xml (XML) — 3KB
02. Unregistered Sales of Equity Securities
Item 3.02. Unregistered Sales of Equity Securities. The information set forth in Item 3.02 of the Original Form 8-K is hereby supplemented as follows: In connection with the completion of the Transaction, 102,298,808 shares of the Company's Class A common stock are issuable to those with rights to receive such shares pursuant to the Transaction (including shares issued in exchange for ordinary shares of Exscientia outstanding as of the effective time of the Scheme of Arrangement as well as shares issuable with respect to Exscientia Share Options or Exscientia RSUs that were canceled in exchange for the right to receive shares of the Company's Class A common stock pursuant to the Transaction Agreement). Such shares are being issued without registration pursuant to the exemption provided by Section 3(a)(10) under the Securities Act of 1933, as amended.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 26, 2024. RECURSION PHARMACEUTICALS, INC. By: /s/ Christopher Gibson Christopher Gibson Chief Executive Officer